Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503225 | 1.00 | CD274 (0.32) | CD274NPC1RAB9A | |
| SCHEMBL9733790 | 0.84 | CD274 (0.33) | CD274NPC1RAB9A | |
| SCHEMBL26832986 | 0.81 | — | — | |
| SCHEMBL17024347 | 0.81 | — | — | |
| SCHEMBL11500645 | 0.80 | MEN1 (0.32) | CD274 | |
| SCHEMBL9735306 | 0.80 | MEN1 (0.32) | CD274 | |
| SCHEMBL9735303 | 0.80 | MEN1 (0.32) | CD274 | |
| SCHEMBL5553779 | 0.78 | DPP4 (0.35) | CD274NPC1RAB9A | |
| SCHEMBL28492715 | 0.78 | CD274 (0.35) | CD274NPC1RAB9A | |
| SCHEMBL28492716 | 0.78 | CD274 (0.35) | CD274NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3024463-B1 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING AUTISM SPECTRUM DISORDERS AND NEURODEVELOPMENTAL DISORDERS | NEUREN PHARMACEUTICALS LTD (NZ) | 2020-03-25 | — | — | EP | claimed |
| US-20260001882-A1 | PROCESS FOR PREPARING BICYCLIC GLYCINE-PROLINE COMPOUNDS AND MONOCYCLIC GLYCINE-PROLINE INTERMEDIATES THEREOF | NEUREN PHARMACEUTICALS LTD (NZ) | 2026-01-01 | — | — | US | disclosed |
| EP-4419528-A1 | PROCESS FOR PREPARING BICYCLIC GLYCINE-PROLINE COMPOUNDS AND MONOCYCLIC GLYCINE-PROLINE INTERMEDIATES THEREOF | Neuren Pharmaceuticals Limited (NZ) | 2024-08-28 | — | — | EP | disclosed |
| CN-118234729-A | Process for preparing bicyclic glycine-proline compounds and monocyclic glycine-proline intermediates thereof | 诺仁制药有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240132511-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2024-04-25 | — | — | US | disclosed |
| EP-4291192-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | Neuren Pharmaceuticals Limited (NZ) | 2023-12-20 | — | — | EP | disclosed |
| CN-116916921-A | Treatment of Prader-Willi syndrome | 诺仁制药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-09-28 | — | — | US | disclosed |
| WO-2023064991-A1 | PROCESS FOR PREPARING BICYCLIC GLYCINE-PROLINE COMPOUNDS AND MONOCYCLIC GLYCINE-PROLINE INTERMEDIATES THEREOF | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-04-27 | — | — | WO | disclosed |
| US-20220387426-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LTD (NZ) | 2022-12-08 | — | — | US | disclosed |
| US-9119851-B2 | Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals | NEUREN PHARMACEUTICALS, LTD. (NZ) | 2015-09-01 | — | — | US | disclosed |
| WO-2015013397-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING AUTISM SPECTRUM DISORDERS AND NEURODEVELOPMENTAL DISORDERS | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-01-29 | — | — | WO | disclosed |
| US-20140309230-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2014-10-16 | — | — | US | disclosed |
| US-8791117-B2 | Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2014-07-29 | — | — | US | disclosed |
| US-8519127-B2 | Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy | NEUREN PHARMACEUTICALS LIMITED (AU) | 2013-08-27 | — | — | US | disclosed |
| US-20110201614-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-08-18 | — | — | US | disclosed |
| WO-2011037644-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-03-31 | — | — | WO | disclosed |
| US-20110052531-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-03-03 | — | — | US | disclosed |
| US-20090263334-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | BICKERDIKE MIKE JOHN | 2009-10-22 | — | — | US | disclosed |
| WO-2008063311-A2 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052531-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | PMP22, IAPP, GCG | CD274 4326/4885NPC1 2943/4885RAB9A 2901/4885 |
| US-20240132511-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | COMT, HSD17B3, HSD3B1 | CD274 4874/4885NPC1 2075/4885RAB9A 2566/4885 |
| US-20110201614-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | GRIA2, QPCT, GRM2 | CD274 4758/4885NPC1 1683/4885RAB9A 2119/4885 |
| US-20090263334-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | GRIA2, QPCT, GRM2 | CD274 4758/4885NPC1 1683/4885RAB9A 2119/4885 |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | CD274 4812/4885NPC1 785/4885RAB9A 2743/4885 |
| US-20140309230-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | GRIA2, QPCT, GRM2 | CD274 4758/4885NPC1 1683/4885RAB9A 2119/4885 |
| US-20220387426-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | CD274 4812/4885NPC1 785/4885RAB9A 2743/4885 |
| US-20260001882-A1 | PROCESS FOR PREPARING BICYCLIC GLYCINE-PROLINE COMPOUNDS AND MONOCYCLIC GLYCINE-PROLINE INTERMEDIATES THEREOF | GLRA2, GLRB, GLRA1 | CD274 4759/4885NPC1 687/4885RAB9A 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.